Search
Login
ASA is the essential resource to cultivate leadership, advance knowledge, and strengthen the skills of those who work with, and on behalf of, older adults.

Text Resize

A New Era in Alzheimer’s Innovation

Membership Directory

Find ASA members in your area or who share your interest area. Enter a name or click on the magnifying glass to start your search.
 

Closing General Session: A New Era in Alzheimer’s Innovation

Sponsored by PhRMA

Presented by AARP

 

 

 
 

Thursday, March 29 | 8:00–9:30 AM

Alzheimer's disease devastates the minds of patients, creates substantial burdens for families and caregivers and costs the United States billions of dollars each year.  The disease itself is one of the most complex researchers have ever studied.  Despite that, America's biopharmaceutical companies are committed to combatting this devastating disease, with 87 potential new treatments in clinical trials today. However, the path from research to a new medicine is extremely long and complex with many setbacks along the way, particularly in the case of Alzheimer's. Scientists have made progress in unraveling the complexities of the brain and identifying the underpinnings of Alzheimer's, but finding an effective treatment remains a daunting challenge.  Join us to learn more about what the biopharmaceutical industry is doing in the search for treatments and hopefully one day, a cure and the impact this is having on patient's lives.

This session will educate audience members on the work the industry is doing to search for treatments and cures in the Alzheimer's space and beyond, expand on the difficulty of researching and bringing medicines to market, including the high number of failures, and highlight the patient experience and the need for access to therapies. 

Moderated by Lori Reilly, JD, Executive Vice President for Policy, Research & Membership, PhRMA

Presenters: Bob Blancato, MPA, President, Matz, Blancato & Associates; Phyllis Ferrell, MBA, Vice President of the global Alzheimer's Disease Team, Eli Lilly And Company; Eric Karran, PhD, VP, Distinguished Research Fellow, Foundational Neuroscience Center, Abb Vie Inc; Matthew Kennedy, PhD, Director, Early Discovery Neuroscience, Merck & Co. Inc; Brian Kursonis, Founder, withALZmyHeart.com; Jason Resendez, Executiver Director, LatinosAgainstAlzheimer's Coalition and Chief of Staff, UsAgainstAlzheimer's.

Stay Connected

Follow American Society on Aging on Facebook   Follow American Society on Aging on LinkedIn   Follow American Society on Aging on Twitter   Subscribe eNewsletter   

Events

ASA-USC online courses begin Event Details
Preparing Community-Based Organization Leadership Teams to Tackle Health IT Challenges Event Details
16th Annual Rocky Mountain Geriatrics Conference Event Details

Jobs

AgeBlog

posted on 07.30.2018

Why do employers retain black workers when labor markets are tight, only to lay them off when downturns hit?  Read More

posted on 07.30.2018

Many don’t realize how often law enforcement encounters people with dementia in the community.  Read More